How Pfizer Warning Letter Tarnished Sandoz/Momenta's Glatopa Launch
Executive Summary
An FDA warning letter to a contract manufacturer, Pfizer, delayed Sandoz/Momenta's Glatopa 40 mg launch, reducing projected revenues and leading Momenta to consider selling assets.
You may also be interested in...
Pfizer India Site Slammed By FDA
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.
FDA Warning Letter Slams Pfizer Site In India On Sterility Testing, Environmental Monitoring
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.
Pfizer/Mylan: Pending Clash Of Quality Systems Could Determine Fate Of New Firm
After years of Mylan’s “one quality standard,” the merger with Pfizer Upjohn brings another. Which will prevail? Which should prevail?